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Prostate cancer is one of the most prevalent cancers and the second leading cause of cancer-related
deaths in men in the United States. A large number of patients undergo radiation therapy (RT) as a
standard care of treatment; however, RT causes erectile dysfunction (radiation-induced erectile
dysfunction; RiED) because of late side effects after RT that signiﬁcantly affects quality of life of
prostate cancer patients. Within 5 years of RT, approximately 50% of patients could develop RiED.
Based on the past and current research ﬁndings and number of publications from our group, the
precise mechanism of RiED is under exploration in detail. Recent investigations have shown
prostate RT induces signiﬁcant morphologic arterial damage with aberrant alterations in internal
pudendal arterial tone. Prostatic RT also reduces motor function in the cavernous nerve which may
attribute to axonal degeneration may contributing to RiED. Furthermore, the advances in
radiogenomics such as radiation induced somatic mutation identiﬁcation, copy number variation
and genome-wide association studies has signiﬁcantly facilitated identiﬁcation of biomarkers that
could be used to monitoring radiation-induced late toxicity and damage to the nerves; thus,
genomic- and proteomic-based biomarkers could greatly improve treatment and minimize arterial
tissue and nerve damage. Further, advanced technologies such as proton beam therapy that
precisely target tumor and signiﬁcantly reduce off-target damage to vital organs and healthy
tissues. In this review, we summarize recent advances in RiED research and novel treatment
modalities for RiED. We also discuss the possible molecular mechanism involved in theSources of support: This work was supported from the startup funds from the University of Maryland, School of Medicine to Dr. Zeljko Vujaskovic.
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162 J. Mahmood et al Advances in Radiation Oncology: JulyeSeptember 2016development of RiED in prostate cancer patients. Further, we discuss various readily available
methods as well as novel strategies such as stem cell therapies, shockwave therapy, nerve grafting
with tissue engineering, and nutritional supplementations might be used to mitigate or cure sexual
dysfunction following radiation treatment.
Copyright ª 2016 the Authors. Published by Elsevier Inc. on behalf of the American Society for
Radiation Oncology. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Prostate cancer is responsible for the second highest
rate of cancer-related deaths in American men.1
Approximately one-half of prostate cancer patients
undergo radiation therapy (RT) as a part of their primary
treatment.2,3 Over the past 15 years, clinical trials have
demonstrated improved prostate cancer-related outcomes
by increasing radiation doses to the prostate along with
frequent addition of androgen deprivation therapy
(ADT).4 Given the large variability in the number of
patients experiencing erectile dysfunction (ED)
(20%-90%), the major predictors of recovery are (1) age
at the time of radiation: the younger the man is, the better
erectile function at the time of treatment and the better the
long-term function is going to be, (2) erectile function at
or before the time of radiation, (3) type of RT causing less
nerve damage of the prostate and the less amount of
surrounding tissues exposed to radiation, the better the
outcome, and (4) the health of erectile tissues. Although
survival rates of prostate cancer patients are high, within
3-5 years of treatment completion, taking the previously
discussed predictors into account, approximately one-half
of these patients will develop ED depending on their age,
baseline function, and comorbidities. Normal erections
generally depend upon 3 processes: increased arterial
blood ﬂow into the penis by neurological initiation, cav-
ernosal smooth muscle relaxation, and restriction of
venous blood outﬂow from the penis.5 Impairment of any
of these processes can lead to ED. The probable mecha-
nisms of radiation-induced erectile dysfunction (RiED)
are depicted in Fig 1.
ED affects the sexual healtherelated quality of life of
cancer survivors; especially men younger than 70 years of
age.6-8 One of the most important factors in predicting
postintervention potency is the age of the patient’s sexual
partner as well. Possible loss of sexual function often
plays an important role in treatment-related decisions
made by patients after their initial prostate cancer diag-
nosis. Along with reducing radiation-induced toxicities,
invention of new tools to mitigate and cure RiED through
extensive research will reduce the ﬁnancial burden on the
health care systems for patients suffering from radiation-
induced normal tissue injuries.History of ED Treatment
The ﬁrst documentation of ED dates back to 2000 BC
when Hippocrates reported a number of cases among
wealthy men of ancient Greece; early ED treatment
involved therapies such as the injection of sheep testis
extract.9 In the 1940s, testosterone was puriﬁed; however,
the results of its use as a treatment for ED were disap-
pointing.10,11 Similarly, the use of androgens, when
compared with placebo, did not increase the ability to
obtain an erection. In 1960, the youth equivalence device,
penis pump, was invented by Osbon and remains one of
the most effective devices to treat ED. In 1995, the US
Food and Drug Administration approved the prescription
medication Caverject (alprostadil) for the treatment of
ED. This drug is injected directly into the base of the
penis 5 minutes before a sexual encounter, which
increases blood ﬂow and produces an erection. Prosta-
glandin, used as an intraurethral suppository, was intro-
duced as a treatment for ED in 1997. Sildenaﬁl (Viagra),
the most common treatment for ED, was US Food and
Drug Administrationeapproved in 1998, followed by
vardenaﬁl (Levitra) and tadalaﬁl (Cialis) in 2003. There
are new gels, pills, and injections in development, all of
which aim to beneﬁt patients experiencing ED. Notably,
these drugs target relaxation of the corpus cavernosum
and do not directly treat neurogenic ED.Radiogenomics and RiED
Radiogenomics is the study of responses to RT and its
relation to genomic variations.12 This approach has the
ability to detect altered protein variants in the database
and identify somatic and germline mutations as well as
copy number variations (CNVs) in altered proteins.13 The
genomic expression can predict intrinsic cellular radio-
sensitivity.14,15 Genetic components, such as single
nucleotide polymorphisms (SNPs) or CNVs, have
recently been shown to cause variability in radiation
sensitivity among individuals.16,17 Integration of these
two genetic components, along with dosimetric and
clinical variables, signiﬁcantly improved prediction of
radiation-induced injuries such as rectal bleeding and ED.
Figure 1 Probable mechanisms of radiation-induced erectile dysfunction. (A) Neuronal damage: there is inﬂammation and neuronal
nitric oxid synthase (nNOS) reduction resulting from radiation therapy (RT) in cavernous nerve. Late RT-mediated effects on cavernous
nerve can lead to erectile dysfunction after 3-5 years. (B) Vascular damage: ﬁbrotic changes in blood vessels resulting from RT resulting
in less blood ﬂow in the erection chamber. (C) Smooth muscle atrophy: the corpus cavernosa undergoes atrophy similar to other muscles
when they go unused.
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CNVs and SNPs may prove to be useful genetic variants
in predicting associated radiation toxicities.18 Interest-
ingly, the ﬁrst radiogenomic genome-wide association
study report was a small pilot study with a sample size of
only 79 patients with ED following RT for prostate can-
cer.19 They identiﬁed a SNP associated with the FSHR
gene that encodes the follicle stimulating hormone re-
ceptor, which is involved in gonad development and
function.20 SNPs causing ED were found to be signiﬁ-
cantly associated with adverse reactions in patients treated
with RT.21,22 The predictive systems for cancer drug
resistance, responses to RT or radiochemotherapy, and
cellular toxicity to RT has shown great promise in
advancement of radiogenomic cancer research.23RT and RiED
Radiation is delivered through multiple methods and
treatment recommendations are based on patient-related
factors (comorbid conditions, urinary function, patient’s
preference), cancer-related factors (risk group, prostate
size), and institutional preferences. All treatment modal-
ities of RT carry a risk of ED. Radiation-based treatments
lead to slowly declining erectile function over 1-3 years.
Because of an overall survival at 5 and 10 years of around
90% and 65%, respectively, it is important to consider
adverse effects and quality of life in addition to disease
control.23
There are new techniques for RT that allow for the
delivery of higher doses of radiation with better cancer
Table 1 Current treatment options for RiED
Treatments Beneﬁts Limitations
PDE5-Is 1. Easy to use
2. Safe for many patients
1. Expensive
2. Numerous side effects
3. Contraindicated with nitrate medications
4. Ineffective for severe RiED or a history of pelvic surgery
Vacuum devices 1. One-time purchase
2. Works well in patients with diabetic
and psychogenic ED
3. Few known side effects
1. Should not be used with a signiﬁcant congenital
bleeding disorder or priapism
2. Difﬁcult to use in obese men with increased lower
abdomen fat
3. May interrupt intercourse
4. Requires proper practice to use correctly
5. Erection may not be ﬁrm enough for proper sexual activity
Penile injections 1. Can be used 5-15 minutes before
intercourse
2. High bioavailability
3. High success rate
1. Injection requires manual dexterity and ability to
perform self-injection
2. Mild to moderate pain after injection
3. Intracavernous injection carries the increased risk of priapism
4. High rate for discontinuation because of side effects
Penile prostheses 1. High success rates
2. For patients when PDE5-Is
are contraindicated or ineffective
1. Invasive
2. Higher rate of complication in patients with obesity
and high blood pressure
3. Uncontrolled postsurgery bleeding, infection,
and scar tissue formation that may require removal
4. Disruption of erection reﬂex
5. Decreased erection duration
6. Irreversible treatment
Penile suppositories 1. Fast onset 1. Expensive
2. Ineffective in many patients
3. Can cause penile pain
4. Wears off quickly
Natural supplements 1. Inexpensive
2. Readily available
1. No deﬁnitive improvement in erections
2. May have contraindications with other medications
3. May contain unknown quantities of potent ingredients
ED, erectile dysfunction; PDE5-Is, phosphodiesterase type 5 inhibitors; RiED, radiation-induced erectile dysfunction.
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RT (IMRT) minimizes the high-dose volume through
precise targeting of the prostate. In addition, use of more
advanced image guidance techniques including Calypso
track the target in real time, whereas RT is delivered to
increase precision and decrease expansions for setup
uncertainty.24-26 In secondary analysis of erectile function
for patients on a dose escalation trial testing 64 versus 74
Gy of 3-dimensional (3D) conformal RT along with 3-6
months of ADT, Mangar et al reported that in 51 patients,
12 remained potent, 22 had reduced potency, and 17 were
impotent at 2 years. A total of 83.3% of impotent patients
received a 50 Gy dose to the penile bulb (PB) compared
with 29.4% of patients who maintained potency at 2
years. They suggested that 50 Gy dose is associated with
a signiﬁcant risk of ED and this should be considered
while selecting dose constraints in future dose escalation
studies.27 Van den Wielen et al found that the incidence
of new-onset ED was 36% and 38% 2 and 3 years post-
RT, respectively.28 Radiation Therapy Oncology Group
(RTOG) 9406 trial data reported by Roach et al showed agreater risk of ED in patients who had a median PB
exposure of >52.5 Gy.29 More recently, patient-reported
outcomes from RTOG 0126, a trial powered to detect a
survival beneﬁt for dose escalation, demonstrated no
difference in ED between IMRT and 3D conformal RT
radiation, even though the PB dose was statistically lower
in the IMRT cohort.30
Owing to their close proximity to the prostate, several
nontarget structures such as the neurovascular bundles,
Crura, and PB often receive signiﬁcant radiation doses,
and radiation injury to these structures has been postu-
lated to be responsible for ED. Girelli et al reported
treatment of 104 prostate cancer patients with IMRT
using a hypofractionated schedule with an integrated
boost.30 Men, who were potent at baseline, showed partial
decrease in erectile function. Combining IMRT, hypo-
fractionation, and a simultaneous integrated boost has
been shown to be a safe and effective treatment option for
prostate cancer patients. Prostate cancer patients treated
with Cyberknife stereotactic body RT exhibited minimal
acute toxicity.31 Prostate-speciﬁc antigen response,
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ment in urinary function compare favorably to data pre-
sented following radical prostatectomy, brachytherapy, or
conventional external beam RT.32
Despite the high proportion of patients treated with
brachytherapy, less is known about its lasting effects on
erectile function. In available reports, rates of ED after
permanent seed implantation have been as high as 50%
within 6 years after treatment.33-35 Although long-term
follow-up is valuable, interpretation of such ﬁndings
can be further complicated by the effects of aging.36,37
Keyes et al established multiple factors that had a nega-
tive long-term impact on erectile function, including
ADT, age, and a history of hypertension. They also found
that each successive 5-year cohort showed a decline in
potency.38 High dose rate brachytherapy was developed
as an alternative for patients who could not undergo
combined low dose rate and external beam RT and has
been used by a few groups with excellent results.39-45 A
recent review of the high dose rate patient outcomes re-
ports that erectile preservation was observed in 57%-89%
of patients.46
Proton therapy (PT) is a cutting edge technique being
used in the treatment of prostate cancer. It allows for less
radiation exposure to the nontargeted normal tissues than
photon-based external beam RT. Hoppe et al recently
reported that potency rates remained high in younger
patients 2 years after PT for prostate cancer and the risk of
urinary incontinence was lowered when compared with
effects of surgery; however, long-term effects are still
unknown and will require further follow-up.47 The
potential advantages of PT compared with IMRT are
evolving. A proton beam transfers a minimal dose of
radiation to the front of the tumor, a maximal dose to the
tumor area itself and minimum off-target dose; hence,
proton therapy is safer for healthy tissue surrounding the
tumor. This may lead to a direct impact on the tumor
leading to fewer harmful side effects and increased tumor
control. Further research is awaited to elucidate the effects
of PT on ED in prostate cancer patients.48-52Current treatment options of RiED
Although treatment of prostate cancer confers
increased risk of ED, there are many additional causes of
ED, both medical and psychosocial, that can contribute to
the sexual heath of an individual patient. Known factors
include, but are not limited to, increasing age, diabetes
mellitus, peripheral vascular disease, smoking, anxiety,
and depression; therefore, treatment should be instituted
using a multifaceted approach including an attempt to
address comorbid conditions that could be exacerbating
RiED. Table 1 demonstrates the current treatment options
for ED patients and the beneﬁts and limitations of each
treatment.Normally, the release of nitric oxide (NO) in the
corpus cavernosum upon sexual stimulation initiates
penile erection. The activation of autonomic nerves
results from sexual stimulation and causes relaxation of
vascular and cavernosal smooth muscle via the release
of NO. Simultaneous release of acetylcholine from
parasympathetic nerve ﬁbers inhibits the sympathetic
release of noradrenaline leading to an increase in blood
ﬂow into the cavernosal space. Activation of endothelial
NOS increases blood ﬂow and synthesis of NO. Syn-
thesis of cyclic guanosine monophosphate, stimulated
by the presence of NO, causes the relaxation of smooth
muscle.
Phosphodiesterase type 5 inhibitors (PDE5Is), such as
sildenaﬁl, have been shown to have high efﬁcacy and
safety rates.53 Ilic et al performed a randomized control
trial of nightly sildenaﬁl versus placebo for 6 months in
27 men treated with radiation for prostate cancer, which
did not demonstrate a beneﬁt in potency.54 Zelefsky et al
reported on 279 patients randomized to 50 mg sildenaﬁl
daily or placebo during and after RT for 6 months and
found overall sexual function was signiﬁcantly improved
with the use of sildenaﬁl at 6 and 12 months using the
International Index of Erectile Function. At 24 months,
men treated with sildenaﬁl maintained signiﬁcantly higher
sexual desire and ability to achieve a functional erec-
tion.55 Although a signiﬁcant proportion of men with
RiED do respond to PDE5Is, a number of patients do not
respond well to such pharmacological intervention, sug-
gesting a need for further investigation into the mecha-
nism and development of novel therapeutics.Animal models evaluating RiED and the molecular
mechanisms
Because of challenges in developing an animal model
that clearly demonstrates the human clinical RiED sce-
nario, the etiology of RiED has not been entirely clear.
Rat is the most common laboratory animal used for
developing models of ED. It was demonstrated that RiED
in rat models using irradiators, which are appropriate for
human use, were not suitable for animal use to deliver
accurate dose of radiation.56-58 Our recently published
paper described the rat model of RiED after targeted
radiation using a small animal image guided irradiation
unit.59 Radiation-induced cell injury is primarily caused
by DNA oxidation. Oxidative stress causes loss of smooth
muscle, ﬁbrosis of cavernous tissue, and dysfunction of
the endothelium. Van der Wielen et al demonstrated
alterations in corpora cavernosal arteries after fractionated
prostate-targeted irradiation.60 Radiation damage to the
arterial supply of the corpora cavernosa causes a chronic
inﬂammatory response driven by oxidative stress that
leads to ED.61 Further investigation is needed to explore
the importance of oxidative stress within the cavernosa.
Figure 2 Probable molecular mechanisms of radiation-
induced erectile dysfunction. Radiation therapy causes increase
in reactive oxygen species, leading to inﬂammation leading to
tissue toxicities. CN, cavernous nerve; mTOR, mechanistic
target of rapamycin; NFK, nuclear factor kappa; ROS, reactive
oxygen; TGF, transforming growth factor.
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postulated that the blood vessel damage occurs within the
penile tissue.26,62,63 It is presumed that RiED is multi-
factorial (Fig 2). Furthermore, Nolan et al recently
reported that prostatic irradiation in a canine model using
stereotactic body RT causes morphologic arterial damage
with altered internal pudendal arterial tone. There was
decreased motor function in the pudendal nerve, which
was attributed to axonal degeneration and loss.64 Overall,
the mechanism of RiED is largely unknown and more
intensive mechanistic studies are needed to develop novel
and effective drugs.Future treatments for RiED
Stem cells in rat model of RiED
Stem cells (SCs) are naturally occurring cells that
repopulate healthy tissue and aid in the repair of damaged
tissue. Qiu et al reported signiﬁcant decrease in erectile
function postradiation and found that injection of adipose-
derived stem cells can ameliorate RiED in a rat model.65
Fandel et al were the ﬁrst to provide evidence that intra-
cavernosal (IC) injected SCs rapidly disappeared from the
injection site and migrated to major pelvic ganglia (MPG)
in rats with cavernous nerve (CN) injury.66 Later, Qiu
et al established RiED as a target for SC therapy andshowed that IC injection of stem cells was able to treat
both acute and chronic CN injury-induced ED.65,67
Kovanecz et al showed that IC injection of SkMSC
(xenogeneic mouse mesenchymal stem cells) alone or in
combination with oral sildenaﬁl was able to normalize
erectile function in rats with CN injury.68 There has been
a lot of progress in this ﬁeld of research. SC trans-
plantation has mostly been done by IC injection, but more
recent studies try alternative routes, such as intravenous
injection, periprostatic injection, and scaffolding.69 To
gain more of an understanding of how SCs exert their
therapeutic effects postradiation treatment, research ef-
forts need to shift the preference for functional outcomes
toward the elucidation of mechanisms.
Shockwave therapy for the treatment of RiED
Low-intensity extracorporeal shock wave therapy
(LiESWT) is a new technology used for the treatment of
ED. It is a noninvasive therapy that induces localized
angiogenesis, increasing the ability to push blood to the
penis and keep it there, through the use of low-intensity
shockwaves to increase penile hemodynamics. The goal
of LiESWT is to restore natural erectile function by
inducing neovascularization, and therefore enhance penile
perfusion, improving erectile function.70 Recent studies
have shown response to treatment in PDE5-I non-
responders and further evidence suggests that LiESWT to
the corpora cavernosa is involved in regaining erectile
function.71,72 Interestingly, there is no study yet reported
on radiation-induced ED and use of LiESWT to date. This
is a novel avenue for future research.
Nutritional supplementation in RiED
Many cultures worldwide accept the use of natural
products and herbal remedies for the improvement of
male sexual health73,74; however, many of these so-called
“natural” products that claim to improve sexual function
have been found to contain undisclosed amounts of pre-
scription pharmaceuticals. A study testing readily avail-
able products found PDE5-I or its analogs in 81% of the
samples tested, 20% of which contained >110% the
highest approved dosage. Another study that analyzed
sexual enhancement products found that 70% of samples
marketed as “natural” contained sildenaﬁl.75
Among thousands of natural products, those contain-
ing red ginseng have been found to have some efﬁcacy.
Red ginseng stimulates NO synthase, increasing the pro-
duction of NO and blood ﬂow into the corpora cavernosa.
Studies in rabbit models have shown dose-dependent
relaxation of smooth muscle within the corpora cavernosa
as well as an increase in intracavernosal pressure.76 It has
been proposed that Ginkgo biloba induces production of
NO in endothelial cells while simultaneously relaxing
vascular smooth muscle cells. In vitro data have shown G.
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relaxation in a rabbit model.77
L-arginine is frequently used as a men’s health sup-
plement. It is the immediate precursor of NO, elevating
NO production when consumed. A study by Medeiros
et al on RiED and nutritional supplements reported that
L-arginine or L-glutamine supplementation can have pro-
tective effects against the structural changes of the rat
penis resulting from radiation. Using L-arginine or
L-glutamine as nutritional supplements prevents these
changes, and supplementation with L-arginine showed
slightly more favorable results, making these amino acids
a potential preventive treatment for RiED.78
Nerve graft and tissue engineering
During radical prostatectomy, there have recently been
surgical nerve graft procedures that have had favorable
outcomes, resulting in a rediscovered interest for the
applications of neural repair in a urologic setting. Currently,
the gold standard of treatment is using an autologous donor
graft in the nerve repair procedure, but donor availability
and sitemorbidity are still a problem. Connolly et al used an
“off-the-shelf” acellular nerve graft, hoping it would be a
viable substitute in a ratmodel and demonstrated signiﬁcant
improvement in erectile function.79 Chen and colleagues
used a rabbit model to try to bioengineer entire pendular
penile bodies by seeding endothelial cells and smooth
muscle onto 3D corporal collagen matrices. Theywere able
to create a neo corpora that showed good intracorporeal
pressures needed to achieve an erection and the ability to
induce relaxation when exposed to NO. They also per-
formed mating assessments that revealed an 83% intra-
vaginal ejaculation rate.80,81
RT can cause ED via radiation-induced nerve damage.
In the penis, a decrease in the number of erection-
inducing nerves has been shown in response to radiation
exposure. Although the cause of ED after RT is not
understood fully, penile endothelial dysfunction within
cavernosal tissue and cavernous nerve hypoxia and
ﬁbrosis is the likely mechanism.
Conclusions
Overall, there have been very few published manu-
scripts on RiED, both original and review. There are
several potential therapeutic candidates that demonstrate
some promise in reducing ED without RT. However,
there are still signiﬁcant challenges to overcome before
widespread human application. Important issues, such as
reliable outcomes, safety risks regarding genomic or
epigenetic changes in the longer term as well as potential
immune reactions and infection risks need to be identiﬁed
in more stringent clinical trials. Therefore, extensive
research is required for developing novel strategies tomitigate RiED, which will lead to improved quality of life
of prostate cancer patients.Acknowledgment
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